Neocortical cholinergic activities differentiate lewy body dementia from classical Alzheimer’s disease

Elaine K. Perry, Vahram Haroutunian, Kenneth L. Davis, Raymond Levy, Peter Lantos, Sarah Eagger, Mrinalini Honavar, Andrew Dean, Martin Griffiths, Ian G. McKeith, Robert H. Perry

Research output: Contribution to journalArticlepeer-review

257 Scopus citations

Abstract

Activity of the enzyme which synthesizes acetylcholine, choline acetyltransferase, was estimated in the neocortex of three series of control and demented cases. Clinically demented cases were divided into those with the classical neuropathological features of Alzheimer’s disease (numerous neocortical plaques and tangles) and those with Lewy bodies in the brain stem and cortex (together with plaques and variable neurofibrillary pathology). In the Lewy body cases neocortical choline acetyltransferase was consistently lower than in the classical Alzheimer- type cases. Two of the Lewy body cases with extremely low cholinergic activity were responders in therapeutic trials of the cholinesterase inhibitor, tacrine, and the combined data suggest that cholinergic therapy may be particularly relevant to patients with Lewy body type dementia.

Original languageEnglish
Pages (from-to)747-749
Number of pages3
JournalNeuroReport
Volume5
Issue number7
DOIs
StatePublished - Mar 1994

Keywords

  • Choline acetyltransferase
  • Cholinergic therapy
  • Cortical lewy bodies
  • Dementia
  • Frontal
  • Parietal and occipital cortex
  • Temporal

Fingerprint

Dive into the research topics of 'Neocortical cholinergic activities differentiate lewy body dementia from classical Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this